EPISODE · Mar 31, 2021 · 15 MIN
AML Research Updates: News from ASH 2020
from Empowered! · host Patient Empowerment Network
AML expert Dr. Jeffrey Lancet shares news from the 2020 American Society of Hematology (ASH) annual meeting. Dr. Lancet sheds light on headlines from the meeting including FLT3 inhibitor research, combination therapies with venetoclax, a promising inhibitor therapy, and shares his optimism about the future of AML treatment.About the Guest: Dr. Jeffrey Lancet is Chair and Program Lead in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, FL. He is nationally and internationally recognized for his clinical research in the field of acute leukemias. Learn more about Dr. Lancet, here.
Embed this episode
Ready to play
AML Research Updates: News from ASH 2020
No transcript for this episode yet
Similar Episodes
No similar episodes found.